Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The intent of this study is to demonstrate the efficacy and safety of Immune Globulin
Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in newly or previously
diagnosed CIDP subjects. Eight courses of treatment with either placebo or IGIV-C will occur
every 3 weeks. Neurological function will be measured by Inflammatory Neuropathy Cause and
Treatment (INCAT) scores. Patients who deteriorate or show no improvement between day 16 and
month 6 will receive the alternate study drug for an additional 6 months.
Phase:
Phase 3
Details
Lead Sponsor:
Grifols Therapeutics Inc. Grifols Therapeutics LLC
Treatments:
Antibodies gamma-Globulins Immunoglobulin G Immunoglobulins Immunoglobulins, Intravenous Rho(D) Immune Globulin